期刊文献+

垂体瘤26例就诊原因分析

Etiology of pituitary tumor in 26 patients
原文传递
导出
摘要 对内科门诊近2年来初次诊断为垂体瘤的26例患者就诊原因进行分析,结果显示患者常以高血压、糖尿病、肥胖、月经紊乱等就诊,此外,男性乳房发育、视野缺损、头痛等也可能为首发情况。提示强化对其多样临床表现的认识具有重要的作用。 We retrospectively analyzed the etiology of 26 new-onset pituitary neoplasms, which were diagnosed at outpatient department of internal medicine over the last 2 years. Our results showed that most patients visited doctors for hypertension, diabetes, obesity, and menstrual cycle disorder. In addition, gynecomastia, visual field defect, and headache could also be the primary condition. This study indicates that it should be critical to raise awareness of diverse clinical manifestation of pituitary neoplasm.
出处 《中华全科医师杂志》 2008年第10期705-706,共2页 Chinese Journal of General Practitioners
关键词 垂体肿瘤 症状 临床分析 治疗方法 Pituitary neoplasm Diagnosis
  • 相关文献

参考文献3

  • 1胡吉,胡仁明.垂体瘤的内科治疗[J].国外医学(内分泌学分册),2005,25(4):272-274. 被引量:8
  • 2Gittoes NJ, McCabe C J, Verhaeg J, et al. Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. J Clin Endocrinol Metab, 1997, 82 : 1960-1967.
  • 3Yamada S, Ohyama K, Taguchi M, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery, 2007, 61:580-585.

二级参考文献13

  • 1Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab, 2004,89:1704-1711.
  • 2Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med, 2003,349: 2023-2033.
  • 3Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab,2001,86:3809-3814.
  • 4Mangupli R, Lisette A, Ivett C, et al. Improvement of acromegaly after octreotide LAR treatment. Pituitary, 2003,6: 29-34.
  • 5Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab, 2003, 88: 3090-3098.
  • 6Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab, 2003,88: 5258-5265.
  • 7Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab,2004,89:1577-1585.
  • 8Parkinson C, Kassem M, Heickendorff L, et al. Pegvisomant-induced serum insulin-like growth factor-Ⅰ normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab, 2003,88: 5650-5655.
  • 9Ferone D, Pivonello R, Lastoria S, et al. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinacmic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol, 2001,54:469-477.
  • 10Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab, 2004,89: 2452-2462.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部